Education and Training
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
To assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by power Doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- diagnostic test: Doppler Ultrasound
- device: SIEMENS S3000 and Verasonics Vantage 256
- drug: Vascular Endothelial Growth Factor Receptor 2 tyrosine kinase inhibitor plus immune checkpoint inhibitor
Eligibility
Inclusion Criteria:
- 18 years of age or older
- Pathology-confirmed diagnosis of metastatic RCC
- At least one tumor lesion greater than 1 cm in diameter, amenable to ultrasound
imaging
- Written informed consent.
Specific inclusion criteria:
- arm 1: planned to be treated with combination of VEGFR2 tyrosine kinase inhibitor
(TKI) plus immune checkpoint inhibitor (ICI)
- arm 2: planned to be treated with non-ICI therapy
Exclusion Criteria:
-Any comorbid condition that, in the opinion of the treating provider or the Protocol
Directors, compromises the participant's ability to participate in the study
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Christian Hoerner, PhD
650-721-3206
Not Recruiting